Holen Sie sich die Stockscreener-App
1.17
6.36%
0.07
Handel nachbörslich:
1.17
Schlusskurs vom Vortag:
$1.10
Offen:
$1.1
24-Stunden-Volumen:
111.18K
Relative Volume:
0.37
Marktkapitalisierung:
$59.28M
Einnahmen:
$96.63M
Nettoeinkommen (Verlust:
$-63.32M
KGV:
-0.8014
EPS:
-1.46
Netto-Cashflow:
$-54.55M
1W Leistung:
-1.68%
1M Leistung:
-31.18%
6M Leistung:
-59.23%
1J Leistung:
-70.00%
1-Tages-Spanne:
$1.10
$1.20
1-Wochen-Bereich:
$1.02
$1.2399
52-Wochen-Spanne:
$1.01
$4.65
Akoya Biosciences Inc Stock (AKYA) Company Profile
Firmenname
Akoya Biosciences Inc
Sektor
Telefon
855.896.8401
Adresse
100 CAMPUS DRIVE, MARLBOROUGH
Vergleichen Sie AKYA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKYA
Akoya Biosciences Inc
|
1.17 | 59.28M | 96.63M | -63.32M | -54.55M | -1.46 |
|
ISRG
Intuitive Surgical Inc
|
478.74 | 175.60B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
199.88 | 57.39B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
93.31 | 45.22B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
214.08 | 31.43B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.79 | 15.88B | 3.90B | 392.30M | 288.10M | 1.95 |
Akoya Biosciences Inc Stock (AKYA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-15 | Herabstufung | Craig Hallum | Buy → Hold |
| 2024-08-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-08-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-21 | Eingeleitet | Craig Hallum | Buy |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Buy |
| 2022-11-03 | Eingeleitet | CapitalOne | Overweight |
| 2022-10-06 | Eingeleitet | Stephens | Overweight |
| 2022-06-22 | Eingeleitet | BTIG Research | Buy |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-05-11 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-05-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-05-11 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-05-11 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Akoya Biosciences Inc Aktie (AKYA) Neueste Nachrichten
Kent Lake Files Definitive Proxy Statement and Sends Letter to Quanterix Shareholders - Business Wire
Akoya Biosciences (NASDAQ:AKYA) Given New $1.65 Price Target at Piper Sandler - Defense World
Tikvah Management Calls on Quanterix to Explain the Egregious Te - GuruFocus
Tikvah Management Calls on Quanterix to Explain the Egregious Terms of Convertible Notes Purchased from Akoya Biosciences - Bluefield Daily Telegraph
Quanterix Faces Investor Backlash: $30M Convertible Notes Deal Under Fire - Stock Titan
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Recommendation of “Hold” by Analysts - Defense World
Akoya Biosciences stock hits 52-week low at $1.07 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.07 amid market challenges - Investing.com India
Quanterix Under Fire: Top Investor Warns of 'Value Destructive' $30M Deal with Struggling Akoya - Stock Titan
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – OPTN, SLRN, AKYA, SHYF - GlobeNewswire Inc.
Akoya BiosciencesOn April 2, Entered Securities Purchase Agreement With Quanterix Corporation - MarketScreener
Spatial Genomics and Transcriptomics Industry Analysis Report 2025, Featuring Detailed Profiles of Leading Players10x Genomics, Bruker Corp., Akoya Biosciences, and Bio-Techne Among OthersResearchAndMarkets.com - Bluefield Daily Telegraph
Akoya Biosciences and Team SAMBAI Announce Selection of the - GlobeNewswire
Akoya Biosciences And Team SAMBAI Select PhenoCycler-Fusion For Cancer Equity Research - Nasdaq
Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities - Yahoo Finance
Short Interest in Akoya Biosciences, Inc. (NASDAQ:AKYA) Decreases By 30.8% - The AM Reporter
Akoya Biosciences, Inc. (NASDAQ:AKYA) Short Interest Down 30.8% in March - Defense World
Akoya Biosciences stock hits 52-week low at $1.39 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.39 amid market challenges - Investing.com India
This Waters Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Akoya Biosciences’ (AKYA) Equal Weight Rating Reaffirmed at Stephens - Defense World
Akoya Biosciences Shares Fall After Downgrade From Stephens - MarketScreener
Goldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
This Brown & Brown Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Stephens Downgrades Akoya Biosciences to Equalweight From Overweight, Price Target is $1.80 - Marketscreener.com
Tikvah to oppose Quanterix-Akoya Biosciences merger By Investing.com - Investing.com Australia
Tikvah to oppose Quanterix-Akoya Biosciences merger - Investing.com India
Tikvah Management Announces Intention to Vote AGAINST Quanterix’s Proposed Merger with Akoya Biosciences - Business Wire
Tikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences - Marketscreener.com
Key Investor Fights Back: Quanterix Merger Under Fire Over Valuation Concerns - Stock Titan
Akoya Biosciences (AKYA) to Release Quarterly Earnings on Monday - Defense World
Akoya Biosciences Reports 2024 Financial Results - TipRanks
Akoya Biosciences (AKYA) Reports Q4 Loss, Lags Revenue Estimates - MSN
Stephens Reaffirms “Overweight” Rating for Akoya Biosciences (NASDAQ:AKYA) - The AM Reporter
Akoya Biosciences (NASDAQ:AKYA) Receives Overweight Rating from Stephens - Defense World
Akoya Biosciences Shares Down 6.4% After Stock Offering… -June 08, 2023 at 10:10 am EDT - Marketscreener.com
Akoya Biosciences stock hits 52-week low at $1.43 amid market challenges By Investing.com - Investing.com South Africa
Akoya Biosciences stock hits 52-week low at $1.43 amid market challenges - Investing.com Australia
Akoya: Q4 Earnings Snapshot - Milford Mirror
Akoya Biosciences earnings missed by $0.01, revenue topped estimates - Investing.com Australia
Akoya Biosciences, Inc. Q4 Loss Decreases, But Misses Estimates - Nasdaq
Akoya Biosciences, Inc. SEC 10-K Report - TradingView
Kent Lake urges Quanterix to address questions regarding Akoya deal -March 17, 2025 at 04:28 pm EDT - Marketscreener.com
Akoya Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Akoya Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results Amid Pending Acquisition by Quanterix Corporation - Nasdaq
Akoya Reports Fourth Quarter of 2024 and Full Year Financial Results - GlobeNewswire
Quanterix Merger Under Fire: Top Investor Reveals Shocking 82% Value Disparity - Stock Titan
Kent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today’s Earnings Call - Bluefield Daily Telegraph
Akoya Biosciences, Inc. (NASDAQ:AKYA) Given Consensus Rating of “Hold” by Brokerages - Defense World
Quanterix Shareholder Opposes Proposed Akoya Biosciences Merger -March 11, 2025 at 10:40 am EDT - Marketscreener.com
Quanterix Merger Under Fire: 7.25% Stakeholder Reveals Shocking Valuation Concerns - StockTitan
Finanzdaten der Akoya Biosciences Inc-Aktie (AKYA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Akoya Biosciences Inc-Aktie (AKYA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| McKelligon Brian | President and CEO |
Jun 11 '24 |
Sale |
2.08 |
7,500 |
15,630 |
224,733 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Option Exercise |
0.30 |
7,500 |
2,272 |
232,233 |
| McKelligon Brian | President and CEO |
Jun 06 '24 |
Sale |
2.01 |
7,500 |
15,064 |
224,733 |
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):